test bank for pharmacotherapeutics for nurse practitioner prescribers 3rdedition by woo

,ChapterW 1:W TheW RoleWofW theW NurseW PractitionerWasW Prescriber

MultipleW Choice
IdentifyWtheWchoiceWthatWbestWcompletesWtheWstatementWorWanswersWtheWquestion.

_ 1.W NurseWpractitionerW prescriptiveW authorityW isWregulatedW by:
A. TheW NationalW CouncilW ofWStateW BoardsWofWNursing
B. TheW U.S.WDrugW EnforcementW Administration
C. TheW StateWBoardWofWNursingW forW eachWstate
D. TheW StateWBoardWofWPharmacy

_ 2.W PhysicianW AssistantW (PA)WprescriptiveW authorityW isWregulatedW by:
A. TheW NationalW CouncilW ofWStateW BoardsWofWNursing
B. TheW U.S.WDrugW EnforcementW Administration
C. TheW StateW BoardW ofWNursing
D. TheW StateWBoardW ofWMedicalW Examiners

_ 3.W ClinicalW judgmentW inWprescribingW includes:
A. FactoringW inW theWcostWtoW theW patientW ofWtheW medicationW prescribed
B. AlwaysW prescribingW theWnewestWmedicationW availableW forWtheWdiseaseWprocess
C. HandingW outW drugWsamplesW toWpoorWpatients
D. PrescribingW allWgenericW medicationsW toWcutWcosts

_ 4.W CriteriaW forWchoosingW anWeffectiveW drugW forWaWdisorderWinclude:
A. AskingW theWpatientWwhatWdrugWtheyWthinkW wouldW workWbestWforWthem
B. ConsultingW nationallyW recognizedW guidelinesW forWdiseaseWmanagement
C. PrescribingW medicationsWthatW areWavailableW asWsamplesW beforeW writingW aWprescription
D. FollowingW U.S.WDrugW EnforcementW AdministrationW (DEA)W guidelinesW
forWprescribing
_ 5.W NurseWpractitionerW practiceW mayWthriveW underWhealth-careW reformWdueWto:
A. TheWdemonstratedWabilityWofWnurseWpractitionersWtoWcontrolWcostsWandWimproveWpatient
Woutcomes
B. TheWfactWthatWnurseWpractitionersW willWbeWableWtoWpracticeWindependently
C. TheWfactWthatWnurseWpractitionersW willWhaveWfullW reimbursementW underWhealth-
careWreform
D. TheW abilityW toWshiftW accountabilityW forWMedicaidW toWtheW stateWlevel

,ChapterW 1:W TheW RoleWofW theW NurseW PractitionerWasW Prescrib
erWAnswerW Section

MULTIPLEW CHOICE

1. ANS:W C PTS:WWW 1
2. ANS:W D PTS:WWW 1
3. ANS:W A PTS:WWW 1
4. ANS:W B PTS:WWW 1
5. ANS:W A PTS:WWW 1
ChapterW 2:W ReviewW ofW BasicW PrinciplesW ofWPharmacology

MultipleW Choice
IdentifyWtheWchoiceWthatWbestWcompletesWtheWstatementWorWanswersWtheWquestion.

_
1.W AWpatient’sW nutritionalW intakeW andWlabWworkWreflectsW hypoalbuminemia.W ThisW isWcr
iticalW toWprescribingW because:
A. DistributionW ofWdrugsW toWtargetW tissueW mayWbeWaffected
B. TheW solubilityW ofWtheWdrugW willW notWmatchW theW siteW ofWabsorption
C. ThereW willW beWlessW freeW drugW availableWtoWgenerateW anWeffect
D. DrugsW boundW toWalbuminW areWreadilyW excretedW byWtheW kidney
_ 2.W DrugsW thatW haveW aWsignificantW first-passW effect:
A. MustWbeWgivenW byWtheWenteralW (oral)W routeW only
B. BypassWtheWhepaticWcirculation
C. AreWrapidlyW metabolizedW byWtheWliverW andW mayWhaveW littleW ifWanyW desiredW action
D. AreWconvertedW byWtheW liverW toWmoreW activeW andWfat-solubleW forms

_ 3.W TheW routeW ofWexcretionW ofWaWvolatileW drugW willW likelyW be:
A. TheWkidneys
B. TheWlungs
C. TheWbileWandWfeces
D. TheWskin

_
4.WMedroxyprogesteroneW(DepoWProvera)WisWprescribedWIMWtoWcreateWaWstorageWreservoirW
ofWtheWdrug.W StorageW reservoirs:
A. AssureWthatWtheWdrugWwillW reachWitsWintendedW targetWtissue
B. AreWtheW reasonWforW givingW loadingW doses
C. IncreaseW theW lengthWofWtimeW aWdrugW isW availableW andW active
D. AreWmostWcommonW inWcollagenW tissues

_ 5.W TheW NPWchoosesW toWgiveW cephalexinW everyW 8WhoursW basedWonWknowledgeW ofW theW drug’s:
A. PropensityW toWgoWtoWtheWtargetWreceptor
B. BiologicalW half-life
C. Pharmacodynamics
D. SafetyWandWsideWeffects

_
6.W AzithromycinW dosingW requiresW theW firstW day’sWdoseWbeWtwiceW thoseW ofWtheW otherW 4Wda
ysWofWtheWprescription.WThisW isW consideredW aWloadingW dose.WAWloadingW dose:
A. RapidlyW achievesW drugWlevelsW inWtheWtherapeuticW range
B. RequiresW fourW toWfiveW half-livesW toWattain

, C. IsWinfluencedWbyWrenalW function
D. IsWdirectlyW relatedW toWtheW drugWcirculatingW toWtheW targetWtissues

_
7.WTheW pointW inWtimeW onWtheWdrugW concentrationW curveW thatW indicatesW theW firstW signW ofWaWt
herapeuticWeffectW isW the:
A. MinimumW adverseWeffectWlevel
B. PeakWofWaction
C. OnsetWofWaction
D. TherapeuticW range
_ 8.W PhenytoinW requiresW aWtroughWlevelW beWdrawn.WPeakWandWtroughW levelsW areWdone:
A. WhenWtheWdrugWhasWaWwideWtherapeuticW range
B. WhenWtheW drugWwillW beWadministeredWforWaWshortW timeW only
C. WhenWthereW isW aWhighW correlationW betweenWtheW doseWandWsaturationW ofWreceptorWsites
D. ToWdetermineWifW aWdrugWisW inWtheW therapeuticW range

_
9.W AWlaboratoryW resultW indicatesW theWpeakWlevelW forWaWdrugW isWaboveW theWminim
umW toxicWconcentration.W ThisW meansW thatW the:
A. ConcentrationW willW produceWtherapeuticW effects
B. ConcentrationW willW produceWanWadverseW response
C. TimeW betweenWdosesWmustW beWshortened
D. DurationW ofWactionW ofWtheWdrugW isWtooWlong

_ 10.W DrugsWthatWareWreceptorWagonistsW mayWdemonstrateW whatWproperty?
A. IrreversibleW bindingW toWtheW drugWreceptorWsite
B. Up-regulationW withWchronicW use
C. DesensitizationW orWdown-regulationW withW continuousWuse
D. InverseWrelationshipW betweenWdrugWconcentrationW andWdrugWaction

_ 11.W DrugsW thatW areWreceptorWantagonists,W suchWasWbetaWblockers,W mayWcause:
A. Down-regulationW ofWtheWdrugWreceptor
B. AnWexaggeratedW responseWifWabruptlyW discontinued
C. PartialW blockadeW ofWtheW effectsW ofWagonistWdrugs
D. AnWexaggeratedW responseW toWcompetitiveW drugWagonists

_ 12.W FactorsWthatWaffectW gastricWdrugWabsorptionWinclude:
A. LiverW enzymeW activity
B. Protein-bindingW propertiesW ofWtheWdrugWmolecule
C. LipidW solubilityW ofWtheWdrug
D. AbilityW toWchewWandWswallow

_ 13.W DrugsWadministeredW viaWintravenousW (IV)Wroute:
A. NeedWtoWbeWlipidW solubleW inWorderWtoWbeWeasilyW absorbed
B. BeginW distributionW intoW theW bodyWimmediately
C. AreWeasilyW absorbedWifWtheyWareWnonionized
D. MayWuseW pinocytosisW toWbeWabsorbed

_
14.W WhenWaWmedicationW isW addedWtoWaWregimenW forW aWsynergisticWeffect,W theW combinedW e
ffectW ofWtheWdrugsW is:
A. TheW sumW ofWtheWeffectsW ofWeachWdrugWindividually
B. GreaterW thanW theWsumW ofWtheW effectsW ofWeachWdrugWindividually
C. LessWthanW theWeffectW ofWeachW drugWindividually
D. NotWpredictable,WasWitW variesW withW eachWindividual